IV
Bioprocessing consumables & resins
Biologics manufacturing runs on single-use bags, filters and protein-A resin from an oligopoly with razor-blade economics.
Biologics don't fail at the molecule. They fail at the filter, the bag, and the resin column — and those are made by a handful of suppliers running razor-and-blade economics. A monoclonal antibody batch is captured on Protein A affinity resin, polished on ion-exchange media, clarified through depth and sterile filters, and mixed and stored in single-use bags and assemblies. Each is a qualified, validated, regulator-locked consumable: once a plant files its process with the FDA, swapping a filter membrane or resin ligand means re-validation, so installed base converts into recurring, sticky consumable pull for the life of the drug.
Who owns it
The choke is an oligopoly. Danaher's Cytiva is the Protein A and chromatography-hardware incumbent (the X-platform bioreactors, MabSelect resin line). Sartorius Stedim Biotech is the single-use bag, filter and bioreactor pure-play. Merck KGaA's MilliporeSigma supplies filtration, resins and single-use through its Process Solutions unit. Thermo Fisher sells bioproduction media and single-use. Underneath them sits Repligen, which makes the alkaline-stable Protein A ligand that Cytiva and MilliporeSigma build into their own branded resins — a supplier-to-the-suppliers position, plus its own OPUS columns, filtration and analytics. Repligen's Protein A ligand also underpins a long-term supply agreement with Purolite (Ecolab), the agarose base-resin maker. The dependency chain is short and deep.
What breaks it
The constraint is qualification, not chemistry. Protein A affinity capture is the dominant, standard capture step for antibodies (non-affinity alternatives exist but are not yet mainstream), and the alkali-stable ligand is held by a few players. A drug's batch record names the specific consumable, so demand is locked to installed processes and new-program approvals rather than price. That same stickiness is the risk: 2023–2024 saw a brutal destocking cycle as customers burned down COVID-era inventory, and consumable revenue fell even as end-demand held. The inflection is now real but uneven — Repligen's Q1 2026 printed +15% reported / +11% organic with consumables up double digits, and Danaher guided 2026 to high-single-digit bioprocessing growth. Customer concentration (large biopharma plus a CDMO layer) and China policy exposure are the structural fragilities.
What forces the reprice
Three tapes. First, the demand-inflection tape: each quarter where consumable order growth holds double digits confirms destocking is fully behind the group and re-rates the multiple from trough toward the historical 8–10% structural grower. Second, the FDA/manufacturing tape — new-molecule approvals, capacity startups and shortage actions that pull qualified consumables. Third, the policy tape: the BIOSECURE Act became law on December 18, 2025 inside the FY2026 NDAA. It does not name specific firms; instead it keys off the DoD list, with the OMB designation of "biotechnology companies of concern" due by December 18, 2026 and FAR rules and effective dates stretching into 2027–2028. The reshoring/de-risking-from-China thesis is a multi-year tailwind for Western consumable suppliers, not a 2026 earnings event — and verifying which entities actually land on the list is the live catalyst, not assumed passage.
Be honest about size and earliness
This is a real, profitable choke — but most of these names are not pure plays on it. For Danaher, Merck KGaA and Thermo Fisher, bioprocessing consumables are a fraction of a diversified conglomerate; the chokepoint is a segment line, not the ticker. The two cleaner reads are Sartorius Stedim Biotech (a true bioprocessing pure-play, but US investors only reach it via thin OTC lines) and Repligen ($738M FY2025 revenue, guided to $803–833M in 2026) — small relative to the conglomerates and carrying its own gene-therapy headwind. The Protein A ligand franchise, the most defensible part of the choke, is a minority of even Repligen's revenue. The recovery is confirmed but young: one to two quarters of clean double-digit consumable orders, against a memory of a two-year downcycle. Treat the inflection as in progress, not finished. This is structure and catalyst mapping, not investment advice.
Who owns the choke
Danaher Corporation
FY2025 sales $24.6B, +2% core; Biotechnology segment (Cytiva + Pall) Q4 2025 revenue $2.03B, +9% reported / +6% core. Management guided 2026 to high-single-digit bioprocessing growth and Cytiva launched 20+ new products incl. expanded Xcellerex X-platform 500L/2,000L bioreactors.
- Bull
- Danaher's Cytiva-plus-Pall Biotechnology segment grew 9% reported in Q4 2025 with 2026 high-single-digit bioprocessing guidance and 20+ new Cytiva products, anchoring the consumables oligopoly.
- Bear
- Bioprocessing is one segment of a slow-growing conglomerate that grew only 2% core in FY2025, diluting the franchise's recovery within the broader portfolio.
Merck KGaA (MilliporeSigma)
German science/technology group; ADR MKKGY traded ~$30.97 on 12-Jun-2026 (~$67B mcap). Life Science Process Solutions supplies filtration devices, chromatography resins, single-use systems and process chemicals to biopharma manufacturers. Not to be confused with US-listed Merck & Co (MRK).
- Bull
- Merck KGaA's MilliporeSigma Process Solutions supplies filtration, chromatography resins, single-use systems and process chemicals across the razor-blade bioprocessing oligopoly.
- Bear
- Process Solutions is one unit of a ~$67B diversified science group reachable only via OTC ADR, diluting the bioprocessing recovery within the broader business.
Repligen Corporation
FY2025 revenue $738M (+16% reported, +14% organic); Q1 2026 revenue $194M (+15% reported, +11% organic) with consumables (incl. protein) up double digits and the Proteins franchise growing mid-teens; FY2026 guide $803-833M. Supplies Protein A ligand to Cytiva/MilliporeSigma under OEM agreements and sources base resin from Purolite (Ecolab) via a long-term supply deal.
- Bull
- Repligen grew FY2025 revenue 16% with consumables up double-digits and guides FY2026 to $803-833M, supplying Protein A ligand to Cytiva and MilliporeSigma under OEM agreements.
- Bear
- Repligen depends on OEM customers like Cytiva and MilliporeSigma and on Purolite base-resin supply, leaving it sandwiched between large partners it does not control.
Sartorius Stedim Biotech S.A.
Bioprocessing pure-play (Aubagne, France; ~71.5% owned by Sartorius AG). FY2025 sales ~EUR2.97B (+~7%), with consumables (filters, single-use bags, assemblies) named as the primary growth driver. OTC ticker SDMHF traded ~$205 on 12-Jun-2026 (~$19.8B implied mcap); also accessible via ADR SRTOY.
- Bull
- Sartorius Stedim is a bioprocessing pure-play whose FY2025 sales grew ~7% with consumables named the primary driver, leveraged squarely to the single-use and filtration oligopoly.
- Bear
- It is ~71.5% owned by Sartorius AG and reachable only via thin OTC lines, and recovery hinges on a sustained rebound in biopharma consumables demand.
Sartorius Aktiengesellschaft
Parent holding of the Sartorius Group; controls the bioprocessing pure-play Sartorius Stedim Biotech and 100% of the Lab Products & Services subgroup. ADR SOAGY (representing Sartorius preference shares) traded ~$53 on 12-Jun-2026; the foreign-ordinary OTC line SUVPF is the same preference class. Primary listing Frankfurt (SRT3).
- Bull
- Sartorius AG controls bioprocessing pure-play Sartorius Stedim plus 100% of Lab Products & Services, giving consolidated exposure to the single-use and resin oligopoly.
- Bear
- Exposure comes via a preference-share ADR on a speculative line, and the parent's recovery hinges on the same biopharma consumables rebound driving its subsidiary.
Thermo Fisher Scientific Inc.
Thermo Fisher closed the acquisition of Sanofi's Ridgefield, NJ sterile fill-finish site in September 2025 and announced an additional US$2bn US manufacturing/R&D investment in April 2025; management frames CDMO as the first line of customer reshoring demand and calls its combined sterile network the world's largest fill/finish CDMO.
- Bull
- Thermo Fisher spans five chokepoints, closed Sanofi's Ridgefield fill-finish site, added $2bn US investment, and calls its network the world's largest fill/finish CDMO amid reshoring.
- Bear
- Each chokepoint is one slice of a vast diversified company, so even strong CDMO reshoring demand is diluted within the broader Thermo Fisher portfolio.
Catalyst calendar
- 2026-12-18BIOSECURE Act: OMB list of biotechnology companies of concern due (statutory deadline)highDesignating which Chinese biomanufacturing/CDMO entities are restricted sets the China-de-risking tailwind for Western consumable and resin suppliers, replacing the now-settled question of passage.
- 2026-07-23Sartorius AG H1 2026 resultsmediumReads the single-use consumables (bags, filters, assemblies) demand inflection at the cleanest bioprocessing supplier and confirms whether destocking is fully behind the group.
- 2026-07-28Danaher Q2 2026 resultsmediumCytiva's bioprocessing print tests the company's high-single-digit 2026 growth guide and the durability of the Protein A / single-use recovery at the choke's incumbent.
- 2026-08-04Repligen Q2 2026 resultsmediumA second straight double-digit consumable/Proteins quarter would confirm the demand inflection at the purest US-listed resin/consumables read and pressure a re-rate from trough multiples.